Council approves recommendations for sickle cell, high-cost treatments
An advisory council charged with proposing Medicaid financing models for expensive sickle cell disease therapies and other high-cost drugs and treatments signed off last week on a list of recommendations for policymakers.
To access this content, you must purchase 1 Year Health News Illinois Subscription or 1 Year Group Subscription - Up to 5 Users, or log in if you are a member.
